Volume 1 Issue 4 - 2016
Herbs and Herbal Medicine: The Need for Evidence Based Direction
Mairi Markaki1,2*
1Dietician- Nutritionist, Greece
2Erasmus for Young Entrepreneurs, Germany
*Corresponding Author: Mairi Markaki, Dietician- Nutritionist, Greece.
Received: November 29, 2016; Published: December 13, 2016
Citation: Mairi Markaki. “Herbs and Herbal Medicine: The Need for Evidence Based Direction”. EC Gastroenterology and Digestive System 1.4 (2016): 133-139.
Herbs and herbal substances have been a part of unconventional medical practice since the dawn of medicine, mainly found in folk and traditional applications and deriving from observation, established conventions, experience and spiritual, cultural rituals. Nowadays herbs and plant extracts are the center of attention for westernized industries, scientific clusters and social groups, although the attitude of the majority of scientific community towards this kind of remedies remains negative and skeptical, as there is limited scientific-based knowledge and a scarcity of rigorous conclusions that can be further utilized as official guidelines in conventional medical practice. Thus, it is crucial that herbs and their future use as preventive or therapeutic medicine be the subject of well-designed clinical studies, as the majority of herbs and extracts that have been examined for their effect in the GI system concentrate on IBS and IBD symptoms’ management and don’t provide conclusive results. Apart from that, this area is a promising and wide research tank from socio economic, nutritional and environmental perspective. To this end, there are many significant aspects that should be taken into consideration such as the quality control of herbal medicine, the structure of clear frameworks and legislations as to their use as medicines, the correct selection of the herbal species that may have additional value among the numerous existing ones, the sustainable exploitation of the plants and the potential side effects that may exist and should be further explored. In a nutshell, all the aforementioned facts elucidate the need for deep and substantial research in this unexplored area, which seems to be promising but lacks of scientific background, research foundation and institutional support.
Keywords: Herbs; Herbal Medicine; GI Diseases; Scientific Data; Further Research
CAM: Complementary and Alternative Medicine; GI: Gastrointestinal Disorders; IBD: Inflammatory Bowel Disease; IBS: Irritable Bowel Syndrome; WEFs: Wild Edible Fruits
Herbs and herbal substances have been a part of unconventional medical practice since the dawn of medicine [1]. The foundation of their use to treat or prevent human diseases lies on observation, established conventions, personal experience, past knowledge and other subjective factors that are related to a more arbitrary, cultural, spiritual, ethnic, social and religious basis rather than be acquired from a scientific perspective [2,3]. In other words, the most commonly used herbal supplements and medicine have evolved from folk and traditional applications [1,4-6], mainly in Africa and Asia (such as Traditional Chinese Medicine) [7,8] but nowadays westernized societies are all the more interested in such remedies, as they seek and turn to alternative and natural ways to approach the coveted wellbeing [9,10]. Under this umbrella, herbs, herbal medicine and dietary supplements constitute a specific category of Complementary and Alternative Medicine [2], an abstract term aiming to describe the medical products and practices that are not part of standard medical care, and a definition wide enough to include all alternative services and products that can be regarded as CAM, under educational, socio-economic, cultural and ethnic terms [3]. On the other side of the coin, it is an undeniable fact that the prevailing attitude of the majority of scientific community and medical practitioners is characterized by skepticism about those methods being, mainly reluctant and negative not only to prescribe such medicine but even to support their potential benefits in theoretical assumptions and controversial debates, elucidating herbs as the new placebo [11]. This attitude can be justified from the scarcity of the scientifically based knowledge as to the relation of their impact on human’s health, as well as from the primitive instinct that something so unfamiliar, unknown, groundless and spiritual cannot have worthy practical efficacy.
However, last decades herbs and herbal medicine are the center of attention for industries, scientific clusters [12,13] and social groups [14], mainly because global priorities have changed a lot [3] and they are directed to sustainability, environmental preservation, social equality and empowerment of developing world and people's re-connection with nature and tradition [10]. In parallel, technological breakthroughs enable for new research opportunities and innovation to the health sector, all these contributing to the emergence and exploitation of herbs in many ways, other than the traditional uses [15]. In this context, herbs have many applications in medical practices in general, and more specifically in the digestive system, where their use is by far the most well-known and frequent.
Need for Further Research
As a part of Complementary and Alternative Medicines (CAM), herbs, plant extracts and herbal medicine are the most popular and frequently used category among patients with GI disorders [10,16]. To be more specific, the most recent statistical data reveal that CAM are used by almost 50% of the patients with IBD at least for a short period of time [17] while the use of herbals as treatment of either active or quiescent disease exceeds the proportion of 58% [10]. The same applies to people with IBS, often attempting to self-treat their symptoms with non-prescribed pharmacological regimens and/or complementary and alternative medicines (CAM) [16,18]. Based on the aforementioned, it can be recognized that herbal medicine is rather popular within patients and this conclusion, together with the fact that a growing body of evidence underpin the potential promising utility of specific herbs in GI disorders illustrate once more the need for the establishment of rigorous scientific data. Nonetheless, it goes without saying that due to the limited available scientific knowledge [17,19] most medical practitioners, especially in western societies, are reluctant to implement or prescribe such remedies, and not unjustifiably, as their perceived natural and healthy properties are not sufficient to guarantee effective and safe health outcomes [20].
Available Scientific Data
In general terms, as to the scientific data that examine the association of herbs and herbal medicine with the gastroenterology disorders, the majority of reviews and meta-analyses converge on the fact that there is limited knowledge and a scarcity of research based and high valid conclusions that can be converted into official recommendations and guidelines to be safely and efficiently utilized in conventional medical practice [17,21-23]. However, it is highlighted that there is an increasing interest in their potential unexplored use and therefore an urgent need for qualitative and quantitative deepening into this sector [3,7]. In particular, there are few studies that examine the use of herbs and herbal medicine for the prevention and treatment of upper and low GI diseases and most importantly the vast majority of them are characterized by inadequate methodology, small sample sizes, short term duration, poor quality results and lack of confirming data [21-24]. What is more, they are very heterogeneous and frequently subjected to publication bias [9], not to mention that most of the results derive from either in vitro protocols or preclinical animal testing. Thus, it is crucial that herbs and their future use as preventive medical tools or therapeutic medicine be the subject of larger, well designed clinical studies with high quality and validity (randomized double-blinded placebo-controlled) to obtain more conclusive results that could be incorporated in standard medical care [19,21,25]. To this end, herbal therapeutic substances and remedies should undergo a rigorous testing as potential pharmaceutical drugs, being very cautious when extrapolating and interpreting the data from in vitro studies to in vivo protocols [26], as the possible interaction of the specific constituents and the safety aspects of such herbal remedies may be very heterogeneous, inconclusive and alternating [9,14,27].
In particular, there are many herbs and extracts that have been examined for their effect in the GI system, bust most data can be found in the IBS and IBD symptoms’ management [7,21-23,28]. Most studies on herbs and extracts include single preparations such as Aloe vera, Curcuma species, peppermint oil (which is commonly used, as both a component of prescription medicine and as a constituent of several over-the-counter remedies and is supposed to be beneficial) [21,29], turmeric extract, artichoke leaf [23], cannabinoids [30], mastic gum, tormentil extracts, wormwood herb [25], boswellia serrata [31], as well as compound preparations which seem to be more effective compared to single ones such as Carmint, Chinese herbal medicine, Padma Lax, STW 5 (also known with the trade name Iberogast) [23,24,29], Tong-xie-ning,Tong-Xie-Yao-Fang,C-IBS and DA-IBS formulations [21,22,28]. It is worthy to highlight that the US National Center for complementary and Integrative Health has gathered in a series of brief fact sheets basic information about more than 50 specific herbs or botanicals [2].while World Health Organization has developed and launched a new project called “WHO Traditional Medicine strategy 2014-2023” in order to promote policies and implement action programs that will strengthen the role of traditional medicine in improving population’s health [3]. Furthermore, even fewer data can be collected for the upper GI disorders, as it is reported that active chemical constituents (e.g. tannins and flavonoids), contained in various medicinal plants and their extracts, could have significant antiulcer activity [32], an assumption which derives from in vivo experiments on animal models or traditional folk medicinal use to treat gastric infections, mainly by targeting H. pylori [33,34]. Moreover, it is also supposed that the combination of extracts rather than single components appears to be more effective and promising [7,21,24], especially when it comes to heterogeneous or not fully understood pathological conditions such as functional dyspepsia [23,25].
Socio economic Perspective

Apart from the afore mentioned, there are many more arguments in favour of investing more research opportunities in this field [3,12,14]. To begin with, herbs and herbal treatments are common practices of traditional medicine for various GI diseases in the developing world where there is a lack of sufficient equipment, supplies and human resources [4-6]. Therefore, it is of paramount importance that those traditional applied therapies be scientific examined and founded in order to be used in a wider scale and substantially contribute to the improvement of life quality in underdeveloped countries, where common gastrointestinal disorders can lead to mortality [6]. From socioeconomic perspective, it is also vital to highlight the financial burden that most times is related with such diseases as their management or treatment is generally long term, expensive [36] and unaffordable for many people [37,38]. On the other hand, the cost of herbal therapy will be probably smaller than that of conventional treatment, and this constitutes a key reason for international scientific societies and government organizations [3,12] to financial support the conduction of clinical studies that promote locally available opportunities of drug development with herbs [13]. It would not be very optimistic to declare that pharmaceutical companies must aid to the current knowledge by supporting relevant studies even if their financial gain would be much lower compared to other kinds of treatment, as they are already moving to this direction (roughly 50% of new chemical entities introduced during the past two decades are from natural products) [12,14,26].
Nutritional Perspective

Except for the socioeconomic conditions that indeed prove the need for more research on that field, special attention should be given on the fact that herbs may have added value, mainly because of their natural origin, their nutritional characteristics and interaction with basic human’s regulatory and functional mechanisms [21,22,26]. To be more specific, as to the Digestive and Gastroenterology system, it is often claimed that individual chemical substances derived from plants may have antibacterial [34], antioxidant, anti-inflammatory [39], and immunoregulatory properties [21]. Most theories support that those characteristics can have significant value in this specific system through various mechanisms that are related to the regulation of neurotransmitters and hormones in the enteric nervous system, modulation of smooth muscle motility in the gastrointestinal tract [8], modulation of the hypothalamic-pituitary-adrenal axis, attenuation of intestinal inflammation and restoration of intestinal flora, inhibition of specific modulators, antiplatelet activity [8,25] etc.
Things to consider

There are additional things to consider and examine, when it comes to the manufacture of herbal medicine and their integration in standard medical care either as supplementary of first line treatment [8,9,18,19]. To begin with, quality control is very important [30], as the practices that accompany the conversion of a herb to a medicine as well as the critical hazards are many and should always be very careful defined and implemented [27]. To this end, there are many examples that highlight the need for clear and evidence based frameworks and legislations [3,14,24], such as the environmental conditions that can affect the composition and the concentration of the active ingredients of plant extracts, the specification of the ideal handling and storage practices or the combination of the chemical families with possible medicinal utility [30,40]. What is more, the exact concentration and dose of the constituents of commercial herbal products is another aspect which needs detailed and rigorous investigation, as well as the analytical description of possible interactions of herbal and conventional medicines [26]. Under this umbrella, authenticity and homogeneity of herbs and strict regimes of physical processing and extract manufacturing are critical factors to maintain phytochemical consistency in commercial products [3,14]. It goes without saying that in order to ensure both safety and efficacy of herbal medicine, implementation of and adherence to good agricultural and collection practice, good plant authentication and identification practice, good manufacturing practice before and during the manufacturing process, and good laboratory practice in analysis are necessary [8,41].
Apart from this, there are numerous plants and herbal extracts that may have a therapeutic impact, yet being unknown, unexplored, limited studied or a part of oral traditional knowledge in local livelihoods and tribes still not widespread [4,5]. In the last occasion, the potential exploitation of herbal remedies by developed world for medical reasons requires a compliance to sustainability goals [6] and environmental preservation in order for flora not to be endangered by intense exploitation [1]. As to the unexplored species and components which may have beneficial health outcome, new facts are always emerging and are under examination [14] with promising results such as Bromelain, that has been shown to have anti-inflammatory activities in vitro [31] or specific WEFs which could have many uses because of their phytochemical, toxicological and pharmaceutical potential [4].
Last but not least, herbals – like all drugs – may have side effects which must be further explored, especially when they are prescribed to people with other comorbidities [2,3,9,12,13]. Until recently, most of the published trials showed no serious side effects, as the number and type of the adverse events were similar or fewer than placebo or conventional treatment [2,3,42]. Those effects are limited to minor events like nausea or diarrhea, although it is likely that some of the herbals could lead to serious renal and liver morbidity (eg, hepatic failure) [43], not to mention that is urgent to dive into the long-term safety of herbal treatment, as possible mutagenicity, toxicity and carcinogenicity has not adequately be explored and thus cannot be excluded [4,31,43]. However, it should be pinpointed that in specific GI disorders such as IBD, most of the published herbal therapies appear to have minimal adverse effects so far [3,42].
In conclusion, there is a need for research based and clinically tested knowledge as to the potential pharmaceutical uses of plants, herbs and their extracts in order to acquire deeper understanding of their impact to human’s health and to ensure that their future integration in conventional medical practice will only be implemented after safety, sustainability and health topics are satisfied. This applies not only to the IG diseases but to all body systems that pharmaceutical plants could have added value. It is crucial to realize that there are many opportunities and promising points in this unexplored area, which until recently lacked in scientific background, research foundation and institutional support.
  1. Barbara Schmidt and David M Ribnicky. “A natural history of botanical therapeutics”. Metabolism 57 (2008): S3-S9.
  2. National Center for Complementary and Alternative Medicine.
  3. WHO Traditional Medicine Strategy 2014-2023.
  4. Khan MP and Ahmad M. “Traditional preference of Wild Edible Fruits (WEFs) for digestive disorders (DDs) among the indigenous communities of Swat Valley-Pakistan”. Journal of Ethnopharmacology 174 (2015): 339-354.
  5. Rahman IU., et al. “Contributions to the phytotherapies of digestive disorders: Traditional knowledge and cultural drivers of Manoor Valley, Northern Pakistan”. Journal of Ethnopharmacology 192 (2016): 30-52.
  6. Rokaya MB., et al. “Traditional uses of medicinal plants in gastrointestinal disorders in Nepal”. Journal of Ethnopharmacology 158.A (2014): 221-229.
  7. Chun-Yan Li and Shu-Chuen Li. “Treatment of irritable bowel syndrome in China: A review”. World Journal of Gastroenterology 21.8 (2015): 2315-2322.
  8. Hai-Tao Xiao.,et al. “Traditional Chinese Medicine Formulas for Irritable Bowel Syndrome: From Ancient Wisdoms to Scientific Understandings”. American Journal of Chinese Medicine43.1(2015): 1-23.
  9. Full-Young Chang. “Irritable bowel syndrome: The evolution of multi-dimensional looking and multidisciplinary treatments”. World Journal of Gastroenterology 20.10 (2014): 2499-2514.
  10. Dossett ML., et al. “Complementary and alternative medicine use by US adults with gastrointestinal conditions: Results from the 2012 National Health Interview Survey” American Journal of Gastroenterology 109.11 (2014): 1705-1711.
  11. Ozeh A. “Is the increasing use of evidence-based pharmacotherapy causing the renaissance of complementary medicine?” British Journal of Clinical Pharmacology56.3 (2003): 292-296.
  12. Rishton GM. “Natural products as a robust source of new drugs and drug leads: past successes and present day issues”. American Journal of Cardiology 101.10A (2008): 43D-49D.
  13. Raskin I and Ripoll C. “Can an apple a day keep the doctor away?” Current Pharmaceutical Design 10.27 (2004): 3419-3429.
  14. Evans S. “Changing the knowledge base in Western herbal medicine”. Social Science and Medicine 67.12 (2008): 2098-2106.
  15. Richter R K. “Herbal Medicine: Chaos in the Marketplace”. New York: Haworth Herbal Press (2003).
  16. Kong SC., et al. “The incidence of self-prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases”. Journal of Clinical Gastroenterology 39.2 (2005): 138-141.
  17. Z Hussain and E m Quigle. “Systematic review: complementary and alternative medicine in the irritable bowel syndrome”. Alimentary Pharmacology and Therapeutics23.4 (2006): 465-471.
  18. Spanier JA., et al. “A systematic review of alternative therapies in the irritable bowel syndrome”. Archives of Internal Medicine 163.3 (2003): 265-274.
  19. F Cremonini.l “Standardized herbal treatments on functional bowel disorders: moving from putative mechanisms of action to controlled clinical trials”. Neurogastroenterology and Motility26.7(2014): 893-900.
  20. Adam S Cheifetz., et al. “Complementary and Alternative Medicines Used by Patients With Inflammatory Bowel Diseases”. Gastroenterology (2016).
  21. Roja Rahimi and Mohammad Abdollahi. “Herbal medicines for the management of irritable bowel syndrome: A comprehensive review”. World Journal of Gastroenterology 18.7 (2012): 589-600.
  22. Liu JP., et al. “Herbal medicines for treatment of irritable bowel syndrome”. Cochrane Database Systematic Reviews 1 (2006): CD004116.
  23. Yoon SL., et al. “Management of irritable bowel syndrome (IBS) in adults: conventional and complementary/alternative approaches”. Alternative Medicine Review 16.2 (2011): 134-151.
  24. Shi J., et al. “Effectiveness and safety of herbal medicines in the treatment of irritable bowel syndrome: a systematic review”. World Journal of Gastroenterology 14.3 (2008): 454-462.
  25. Georgia Lazaraki., et al. “Recent advances in pharmacological treatment of irritable bowel syndrome”. World Journal of Gastroenterology 20.27 (2014): 8867-8885.
  26. Ribnicky DM., et al. “Evaluation of botanicals for improving human health”. American Journal of Clinical Nutrition 87.2 (2008): 472S-475S.
  27. Arnold Vlietinck., et al.“Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union”. Planta Medica 75.7 (2009): 683-688.
  28. Grundmann O and Yoon SL. “Complementary and alternative medicines in irritable bowel syndrome: an integrative view”. World Journal of Gastroenterology 20.2 (2014): 346-362.
  29. Shen YH and Nahas R. “Complementary and alternative medicine for treatment of irritable bowel syndrome”. Canadian Family Physician 55.2 (2009): 143-148.
  30. Theodor Bokic., et al. “Potential causes and present pharmacotherapy of irritable bowel syndrome (IBS): an overview”. Pharmacology 96.1-2 (2015): 76-85.
  31. S C Ng., et al. “The efficacy of herbal therapy in inflammatory bowel disease”. Alimentary Pharmacology & Therapeutics 38.3 (2013): 854-863.
  32. G Vimala and F Gricilda Shoba. “A Review on Antiulcer Activity of Few Indian Medicinal Plants”. International Journal of Microbiology (2014).
  33. Maliheh Safavi., et al. “Medicinal plants in the treatment of Helicobacter pylori infections”. Journal Pharmaceutical Biology 53.7 (2015): 939-960.
  34. Hiroaki Takeuchi., et al. “Natural products and food components with anti-Helicobacter pylori activities”. World Journal of Gastroenterology 20.27 (2014): 8971-8978.
  35. W Rösch., et al.“Phytotherapy for functional dyspepsia: A review of the clinical evidence for the herbal preparation STW 5”. Phytomedicine 13.5 (2006): 114-121.
  36. Inadomi JM., et al. “Systematic review: the economic impact of irritable bowel syndrome”. Alimentary Pharmacology & Therapeutics 18.7 (2003): 671-682.
  37. Hungin AP., et al.“Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact”. Alimentary Pharmacology & Therapeutics 21.11 (2005): 1365-1375.
  38. Nellesen D., et al. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation” Journal of Managed Care Pharmacy 19.9 (2013): 755-764.
  39. Mona Ghasemian., et al. “Review of Anti-Inflammatory Herbal Medicines”. Advances in Pharmacological Sciences(2016).
  40. Gerald Holtmann and Nicholas J Talley. “Herbal Medicines for the Treatment of Functional and Inflammatory Bowel Disorders”. Clinical Gastroenterology and Hepatology 13.3 (2015): 422-432.
  41. Nikolaus J Sucher and Suresh Govindaraghavan.“Quality assessment of medicinal herbs and their extracts: Criteria and prerequisites for consistent safety and efficacy of herbal medicines”. Botanicals for Epilepsy Epilepsy Behavior Journal52.B (2015): 363-371.
  42. Lee JY., et al. “Systematic Review of Adverse Effects from Herbal Drugs Reported in Randomized Controlled Trials”. Phytotherapy Research 30.9 (2016): 1412-1419.
  43. Abdualmjid RJ and Sergi C. “Hepatotoxic botanicals - an evidence-based systematic review”. Journal of Pharmacy and Pharmaceutical Sciences 16.3 (2013): 376-404.
Copyright: © 2016 Mairi Markaki. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

July Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the July issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before July 18, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.